Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart mapping method could cut repeat ablations

NCT ID NCT05239364

Disease control Sponsor: Evangelical Hospital Düsseldorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two approaches for treating atrial tachycardia that occurs after atrial fibrillation ablation or heart surgery. One group gets standard ablation targeting all abnormal heart circuits, while the other gets a more focused ablation guided by a new ultra-high-density mapping system. The goal is to see if the targeted approach reduces the chance of arrhythmia coming back. About 100 adults who have had prior AF ablation or heart surgery and now have a stable atrial tachycardia will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation (radiofrequency)
What this could lead to
If successful, this approach could reduce the number of repeat procedures needed for atrial tachycardia after atrial fibrillation treatment or heart surgery.
What could go wrong
This is an early-stage study with 100 participants, so results may not apply to all patients. The procedure carries standard risks of catheter ablation, such as bleeding or heart tissue damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery * Surface ECG-documentation of AT as primary clinical arrhythmia * ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms Exclusion Criteria: * \< 18 years * No previous atrial fibrillation ablation procedure or cardiac surgery * Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment * History of hemorrhagic diathesis or other coagulopathies * Contraindications for oral anticoagulation * Hyper- or hypothyroidism * Has any condition that would make participation not be in the best interest of the subject

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmias, cardiac are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation atrial tachycardia cardiac rhythm disease heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmias, cardiac Atrial tachycardia Heart arrhythmia Heart diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asklepios St. Georg

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Evangelic Hospital Düsseldorf

    RECRUITING

    Düsseldorf, North Rhine-Westfalia, 40217, Germany

  • Evangelic Hospital Hagen-Haspe

    RECRUITING

    Hagen, Germany

  • Städtisches Klinikum Karlsruhe

    RECRUITING

    Karlsruhe, Germany

  • Universitätsklinikum Schleswig Holstein

    RECRUITING

    Kiel, Germany

  • Vivantes Klinikum Am Urban Berlin

    RECRUITING

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.